Bausch Health Companies Inc. (BHC) Financial Statements
Bausch Health Companies Inc. (BHC) reported trailing twelve-month revenue of $10.9B (up 10.1% year on year) and net income of -$1.1B as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $1.4B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BHCBausch Health Companies Inc.Follow BHC — free
—
Price chart with a free account
- Market cap
- 2.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.18 | 2.43 | 3.48 | 5.77 | 8.21 | 10.45 | 9.67 | 8.72 | 8.38 | 8.60 | 8.03 | 8.43 | 8.12 | 8.76 | 9.63 | 10.27 | 10.85 | |
| Gross profit | 0.79 | 1.74 | 2.58 | 3.92 | 6.03 | 7.92 | 7.10 | 6.22 | — | — | — | 6.04 | 5.76 | 6.20 | 6.84 | 7.25 | 7.80 | |
| Research & development | 0.07 | 0.07 | 0.08 | 0.16 | 0.25 | 0.33 | 0.42 | 0.36 | 0.41 | 0.47 | 0.45 | 0.47 | 0.53 | 0.60 | 0.62 | 0.63 | 0.66 | |
| Operating income | -0.11 | 0.30 | 0.08 | -0.41 | 2.00 | 1.53 | -0.57 | 0.10 | -2.38 | -0.20 | 0.68 | 0.45 | 0.45 | 0.96 | 1.55 | 1.81 | 0.88 | |
| Pre-tax income | 0.34 | -0.02 | -0.39 | -1.31 | 1.05 | -0.16 | -2.44 | -1.74 | -4.15 | -1.84 | -0.93 | -1.02 | -0.13 | -0.39 | 0.17 | 0.37 | -0.73 | |
| Income tax | -0.03 | -0.18 | -0.28 | -0.45 | 0.17 | 0.13 | -0.03 | -4.15 | -0.01 | -0.05 | -0.38 | -0.09 | 0.08 | 0.22 | 0.24 | 0.25 | 0.36 | |
| Net income | 0.37 | 0.16 | -0.12 | -0.86 | 0.88 | -0.29 | -2.41 | 2.40 | -4.14 | -1.79 | -0.56 | -0.95 | -0.23 | -0.59 | -0.05 | 0.16 | -1.10 | |
| Diluted EPS ($) | -1.06 | 0.49 | -0.38 | -2.70 | 2.58 | -0.85 | -6.94 | 6.83 | -11.81 | -5.08 | -1.58 | -2.64 | -0.62 | -1.62 | -0.13 | 0.42 | -2.96 | |
| Diluted shares (bn) | 0.196 | 0.326 | 0.305 | 0.321 | 0.342 | 0.343 | 0.347 | 0.352 | 0.351 | 0.352 | 0.355 | 0.359 | 0.362 | 0.365 | 0.368 | 0.375 | — |
USD billions · SEC XBRL
Bausch Health Companies Inc. — questions
- What is Bausch Health Companies Inc.'s revenue?
- $10.9B over the twelve months to 2026-06-30, up 10.1% year on year, from its 10-Q and 10-K filings.
- What is Bausch Health Companies Inc.'s net income?
- -$1.1B over the twelve months to 2026-06-30.
- What is Bausch Health Companies Inc.'s free cash flow?
- $1.4B over the twelve months to 2026-06-30.
- What are Bausch Health Companies Inc.'s diluted earnings per share?
- $-2.96 over the twelve months to 2026-06-30.
Every figure on this page comes from Bausch Health Companies Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.